Chronic kidney disease (CKD) is a major public health problem, estimated to affect 26 million Americans and 200 million individuals worldwide.
1,2 Persons with CKD are at high risk of cardiovascular disease (CVD), progression to end-stage renal disease (ESRD), and all-cause mortality.
3 Hypertension is a well-known risk factor for CVD; therefore, optimal blood pressure (BP) control is a major clinical and public health priority.
4,5 Over the past decade, several studies and clinical practice guidelines
6-10 have addressed the optimal BP target in CKD populations, yet consensus remains elusive. Observational data have demonstrated U-shaped relationships between BP and mortality risk among those with CKD.
11,12 Clinical trials testing different BP targets in CKD populations, including the Modification of Diet in Renal Disease (MDRD)
13 and the African American Study of Kidney Disease and Hypertension (AASK),
14 failed to demonstrate benefits of BP lowering for slowing down CKD progression and were underpowered to address CVD and mortality.